Scientific Advisory Board

//Scientific Advisory Board
Scientific Advisory Board 2018-03-09T14:02:04+00:00

Scientific Advisory Board.

Formed in February 2018 the Metrion Biosciences Scientific Advisory Board (SAB) comprises leading scientists selected for their extensive and diverse experience in ion channel screening, cardiac safety testing, neuroscience research and native tissue and human stem cell translational assays, all of which are fields of interest to Metrion. The SAB is chaired by Dr Keith McCullagh, Metrion’s non-executive Chairman, and members include Dr Marc Rogers, CSO, Metrion, with four external experts:

Professor Annette Dolphin

Professor of Pharmacology, University College London

Annette is an ion channel biologist, with a particular interest in studying voltage-gated calcium channel function. She has many years’ experience running a research lab in academia; for the last 20 years, at University College London, where she is Professor of Pharmacology. She is particularly interested in the physiology and pharmacology of neuronal calcium channels, and in diseases involving these channels. Her research utilises electrophysiology, as well as biochemical and imaging techniques. Her most recent work relates to the role of neuronal calcium channels in the peripheral pain pathway, but her work also encompasses models and mechanisms of neurological and psychiatric diseases involving calcium channel subunits. Annette studied Biochemistry at Oxford University, followed by PhD studies at Institute of Psychiatry in London, where she first became interested in Neuropharmacology. Annette is a Fellow of the Royal Society, a Fellow of the Academy of Medical Sciences and is currently President Elect of the British Neuroscience Association.

David Reynolds PhD

Chief Scientific Officer of Alzheimer’s Research UK

David Reynolds is currently Chief Scientific Officer of Alzheimer’s Research UK, which is UK’s leading research charity aiming to defeat dementia. Previously David worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. David has has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain. David has coordinated Pfizer’s participation in over thirty Innovative Medicines Initiative (IMI) projects. He has served as a member of the Medical Research Council’s Neuroscience and Mental Health Board and is a scientific advisor for two neuroscience biotechnology companies. His is also a Trustee for the UK Dementia Research Institute. David holds a BA in Natural Sciences and a PhD in Neuropharmacology, both from the University of Cambridge.

Tom Colatsky PhD

Principal, Marshview Life Science Advisors

Tom is a trained ion channel biophysicist with over 35 years’ experience in drug development and regulatory science, covering a wide range of screening approaches and therapeutic indications. He has led numerous drug discovery and drug safety programs focused on ion channels targets, working within large and small pharmaceutical/biotechnology companies as well as the US FDA, where he most recently served as Director of the Division of Applied Regulatory Science in the FDA’s Center for Drug Evaluation & Research. Tom has helped to develop effective strategies for the validation, positioning and commercialization of novel breakthrough technologies, including multi-omic approaches to target selection and the use of computer models to replace clinical trials. He is currently a member of the Steering Committee for the In Vitro Comprehensive Proarrhythia Assay (CiPA) initiative and led their In Silico Working Group. Tom has been an Established Investigator of the American Heart Association and was named an AAAS Fellow in Pharmaceutical Sciences for his work on ion channel pharmacology and drug-induced QT prolongation. He has served on numerous expert panels and editorial boards, as well as various NIH and American Heart Association study sections, and is a past President of the Philadelphia Physiological Society.

Professor Chris Denning

Head of Department and Professor of Stem Cell Biology, Nottingham University

Chris has 25 years’ experience in molecular cell biology and is currently Head of Department and Professor of Stem Cell Biology at Nottingham University. His team comprises eight academics and ~60 staff, and he leads the University of Nottingham Priority Area in Regenerative Medicine & Stem Cells. Chris’s research focuses on human pluripotent stem cells and derived cardiomyocytes for use in disease modelling and drug development, including extensive experience in the use the Cas9/CRISPR gene editing system. He developed a ~£2m phenotyping suite in Nottingham and over his career, he has been lead- or co-applicant (or host for five Fellowships) on funded applications totalling £42m, with £27m to Nottingham of which £10m has supported his lab. Chris is on the Board of NC3Rs, Chair of the Skills and Knowledge Transfer Panel, a member of the NC3Rs Prize panel and was on the NC3Rs main panel from as member (2010-12) and Deputy Chair (2013-15). Chris is panel member for the MRC Regenerative Medicine Research Committee and has been co-opted to panels for various European funding agencies. He was Board member of the British Society for Gene & Cell Therapy (2011-16). Chris holds a BSc in Biochemistry with Molecular Biology from the University of Leeds and a PhD in Cancer Gene Therapy from the Beatson Institute for Cancer Research, University of Glasgow.